Medically reviewed by Dr. Jyoti Rao, Consultant, Medical Affairs | Last reviewed August 2026
Key Takeaways
- Mortality in ATTR-CM is generally the result of progressive disease rather than a single isolated event.
- Reserve, rhythm stability, congestion, and stage matter more than the diagnosis alone.
- Stabilizer therapy reduced cardiovascular death and hospitalization in pivotal trials.
- Disease-modifying therapy slows disease progression but does not reverse established cardiac amyloid deposition.
Why Mortality in ATTR-CM Is Cumulative, Not a Single Event
Mortality in ATTR-CM generally reflects progressive disease and the cumulative effects of worsening cardiac dysfunction rather than a single isolated mechanism. Progressive cardiac amyloid deposition, restrictive physiology, congestion, hypotension, arrhythmias, conduction abnormalities, and declining cardiac function commonly coexist in advanced disease and contribute to worsening clinical outcomes over time. These factors contribute collectively to overall risk assessment and prognosis.
Reserve and Stage Matter More Than the Label
Disease stage and overall clinical status are more informative for prognosis than the diagnosis alone. Imaging findings, biomarkers, functional status, rhythm abnormalities, renal function, and frailty all contribute to prognostic assessment and should be interpreted together within the overall clinical context.
What the Survival Evidence Does and Does Not Promise
Disease-modifying therapy remains an important component of treatment, although its benefits may be more limited in advanced disease. In pivotal trials, the transthyretin stabilizer tafamidis reduced mortality and cardiovascular-related hospitalization, and acoramidis improved a hierarchical cardiovascular outcome versus placebo. Exploratory recurrent-event analyses suggest that repeated cardiovascular events provide additional information about disease progression beyond first-event analyses. Clinical benefit is influenced by timely treatment initiation, continued therapy, and the patient's overall clinical status. Comprehensive clinical management, including appropriate follow-up and continued treatment where clinically indicated, remains an important component of patient care.
Frequently Asked Questions
Is ATTR-CM mortality usually sudden?
The final event can be abrupt, but mortality in ATTR-CM is usually the end of a cumulative process of restrictive burden, congestion, arrhythmia, and shrinking reserve rather than a single isolated cause.
What matters most prognostically near end-stage disease?
Disease stage, cardiac function, rhythm abnormalities, congestion, renal function, and frailty are important determinants of prognosis.
Does disease-modifying therapy improve survival?
Pivotal trials showed transthyretin stabilizers reduced mortality and cardiovascular-related hospitalization or improved hierarchical cardiovascular outcomes. Clinical benefit is likely to be greater when treatment is initiated earlier in the disease course and maintained over time, where clinically appropriate.
Can therapy help once the disease is advanced?
Disease-modifying therapy may continue to slow disease progression in advanced ATTR-CM but is not expected to reverse established cardiac amyloid deposition or fixed structural cardiac changes.
Related Reading
Part of the Spotlight On ATTR-CM resource center.
Related Outcomes Topics
Next Clinical Decision
See the Evidence
References:
- World Heart Federation Consensus on Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM). Global Heart
- Best Practices in Specialized Amyloidosis Centers in the United States. Clinical Medicine Insights: Cardiology
- Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy. New England Journal of Medicine
- Efficacy and Safety of Acoramidis in Transthyretin Amyloid Cardiomyopathy. New England Journal of Medicine
- Effect of Acoramidis on Recurrent and Cumulative Cardiovascular Outcomes in ATTR-CM: Exploratory Analysis From ATTRibute-CM. Journal of the American College of Cardiology
- Baseline Characteristics and Secondary Medication Adherence Among Medicare Patients Diagnosed with ATTR-CM and/or Receiving Tafamidis Prescriptions. Journal of Managed Care & Specialty Pharmacy
This content is intended for healthcare professionals for educational purposes and is not a substitute for individual clinical judgment. It was developed with AI assistance and reviewed by a qualified healthcare professional for clinical accuracy prior to publication.